Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 13/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.41 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003286 | 0.80 | MAPK14 (0.41) | NR3C2MAPK14MAPK10 | |
| SCHEMBL13003290 | 0.79 | MAPK14 (0.40) | NR3C2MAPK14MAPK10 | |
| SCHEMBL10273430 | 0.78 | MAPK14 (0.41) | NR3C2MAPK14MAPK10 | |
| SCHEMBL764202 | 0.78 | POLB (0.47) | NR3C2MAPK14MAPK10 | |
| SCHEMBL13003269 | 0.75 | MAPK14 (0.43) | MAPK14MAPK10 | |
| SCHEMBL13003266 | 0.73 | MAPK14 (0.40) | NR3C2MAPK14MAPK10 | |
| SCHEMBL10273945 | 0.73 | MAPK10 (0.45) | NR3C2PRKD1PRKD2BUB1MAPK14 | |
| SCHEMBL13060367 | 0.73 | MAPK14 (0.41) | NR3C2MAPK14MAPK10 | |
| SCHEMBL10273983 | 0.72 | MET (0.43) | MAPK14MAPK10 | |
| SCHEMBL13003262 | 0.69 | MAPK14 (0.44) | MAPK14MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439174-B1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | NR3C2 3/4885PRKD1 2290/4885PRKD2 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.